Details of the Drug Combination

General Information of Drug Combination (ID: DCBUPAP)

Drug Combination Name
Linezolid Moxifloxacin
Indication
Disease Entry Status REF
Community Acquired Pneumonia Phase 3 [1]
Component Drugs Linezolid   DMGFPU2 Moxifloxacin   DMU8V4S
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Linezolid
Disease Entry ICD 11 Status REF
Bacteremia 1A73 Approved [2]
Bacterial infection 1A00-1C4Z Approved [3]
Staphylococcal pneumonia N.A. Approved [2]
Staphylococcus aureus infection N.A. Approved [2]
Coronavirus Disease 2019 (COVID-19) 1D6Y Investigative [4]
Skin infection 1F28-1G0Z Investigative [2]
Linezolid Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bacterial 23S ribosomal RNA (Bact 23S rRNA) TTLFGBV NOUNIPROTAC Binder [7]
------------------------------------------------------------------------------------
Linezolid Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Amine oxidase A (MAOA) OT8NIWMQ AOFA_HUMAN Decreases Activity [8]
Amine oxidase B (MAOB) OTTDFM1O AOFB_HUMAN Decreases Activity [8]
------------------------------------------------------------------------------------
Indication(s) of Moxifloxacin
Disease Entry ICD 11 Status REF
Bacterial infection 1A00-1C4Z Approved [5]
Mycoplasma pneumoniae pneumonia N.A. Approved [6]
Peritonitis N.A. Approved [6]
Pneumonic plague N.A. Approved [6]
Septicemic plague N.A. Approved [6]
Staphylococcal pneumonia N.A. Approved [6]
Staphylococcus aureus infection N.A. Approved [6]
Streptococcal pneumonia N.A. Approved [6]
Tuberculosis 1B10-1B14 Approved [6]
Pneumonia caused by chlamydia N.A. Investigative [6]
Pneumonia due to Klebsiella pneumoniae CA40.03 Investigative [6]
Moxifloxacin Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bacterial DNA gyrase (Bact gyrase) TTN6J5F GYRA_STAAU; GYRB_STAAU Modulator [9]
Staphylococcus Topoisomerase IV (Stap-coc parC) TTIXTO3 PARC_STAAS Modulator [9]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Skin Diseases, Infectious DCKZGIW N. A. Phase 1 [10]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02559310) Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia
2 Linezolid FDA Label
3 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 200222.
4 Therapeutic and Triage Strategies for 2019 Novel Coronavirus Disease in Fever Clinics. Lancet Respir Med. 2020 Mar;8(3):e11-e12.
5 Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8.
6 Moxifloxacin FDA Label
7 Genome sequencing of linezolid-resistant Streptococcus pneumoniae mutants reveals novel mechanisms of resistance. Genome Res. 2009 Jul;19(7):1214-23.
8 Nonclinical Evaluation of Antibacterial Oxazolidinones Contezolid and Contezolid Acefosamil with Low Serotonergic Neurotoxicity. Chem Res Toxicol. 2021 May 17;34(5):1348-1354. doi: 10.1021/acs.chemrestox.0c00524. Epub 2021 Apr 29.
9 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
10 ClinicalTrials.gov (NCT00865280) Study the Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI). U.S. National Institutes of Health.